Literature DB >> 24622764

Comparative effects of gastric bypass and sleeve gastrectomy on plasma osteopontin concentrations in humans.

Andoni Lancha1, Rafael Moncada, Víctor Valentí, Amaia Rodríguez, Victoria Catalán, Sara Becerril, Beatriz Ramírez, Leire Méndez-Giménez, María J Gil, Fernando Rotellar, Secundino Fernández, Javier Salvador, Gema Frühbeck, Javier Gómez-Ambrosi.   

Abstract

BACKGROUND: Bariatric surgery (BS) has proven to be an effective treatment for morbid obesity. Osteopontin (OPN) is a proinflammatory cytokine involved in the development of obesity. The aim of our study was to determine the effect of weight loss following BS on circulating levels of OPN in humans.
METHODS: Body composition and circulating concentrations of OPN and markers of bone metabolism were determined in obese patients who underwent Roux-en-Y gastric bypass (RYGB; n = 40) or sleeve gastrectomy (SG; n = 11).
RESULTS: Patients who underwent RYGB or SG showed decreased body weight (P < 0.001) and body fat percentage (P < 0.001) as well as lower insulin resistance. However, plasma OPN levels were significantly increased after RYGB (P < 0.001) but remained unchanged following SG (P = 0.152). Patients who underwent RYGB also showed significantly increased C-terminal telopeptide of type-I collagen (ICTP) (P < 0.01) and osteocalcin (P < 0.001) while bone mineral density tended to decrease (P = 0.086). Moreover, OPN concentrations were positively correlated with the bone resorption marker ICTP after surgery. On the other hand, patients who underwent SG showed significantly increased ICTP levels (P < 0.05), and the change in OPN was positively correlated with the change in ICTP and negatively with the change in vitamin D after surgery (P < 0.05).
CONCLUSIONS: RYGB increased circulating OPN levels, while they remained unaltered after SG. The increase in OPN levels after RYGB could be related to the increased bone resorption in relation to its well-known effects on bone of this malabsorptive procedure in comparison to the merely restrictive SG.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24622764     DOI: 10.1007/s00464-014-3490-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  60 in total

1.  Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study.

Authors:  Bruno Geloneze; Sylka Rodovalho Geloneze; Elinton Chaim; Fernanda Filgueira Hirsch; Ana Claudia Felici; Giselle Lambert; Marcos Antonio Tambascia; José Carlos Pareja
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

2.  Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients.

Authors:  D Foschi; F Corsi; F Colombo; T Vago; M Bevilaqua; A Rizzi; E Trabucchi
Journal:  J Invest Surg       Date:  2008 Mar-Apr       Impact factor: 2.533

Review 3.  Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery.

Authors:  William R Scott; Rachel L Batterham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-04-06       Impact factor: 3.619

4.  Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats.

Authors:  Kerstin Stemmer; Maximilian Bielohuby; Bernadette E Grayson; Denovan P Begg; Adam P Chambers; Christina Neff; Stephen C Woods; Reinhold G Erben; Matthias H Tschöp; Martin Bidlingmaier; Thomas L Clemens; Randy J Seeley
Journal:  Endocrinology       Date:  2013-04-03       Impact factor: 4.736

5.  Expression profile in omental and subcutaneous adipose tissue from lean and obese subjects. Repression of lipolytic and lipogenic genes.

Authors:  Carmen Hurtado del Pozo; Rosa María Calvo; Gregorio Vesperinas-García; Javier Gómez-Ambrosi; Gema Frühbeck; Miguel Angel Rubio; Maria Jesus Obregon
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

6.  Body-mass index and mortality among 1.46 million white adults.

Authors:  Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

Review 7.  The role of osteopontin in lung disease.

Authors:  Anthony O'Regan
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

8.  Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass.

Authors:  Penelope S Coates; John D Fernstrom; Madelyn H Fernstrom; Philip R Schauer; Susan L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  Plasma osteopontin levels and expression in adipose tissue are increased in obesity.

Authors:  Javier Gómez-Ambrosi; Victoria Catalán; Beatriz Ramírez; Amaia Rodríguez; Inmaculada Colina; Camilo Silva; Fernando Rotellar; Carmen Mugueta; María J Gil; Javier A Cienfuegos; Javier Salvador; Gema Frühbeck
Journal:  J Clin Endocrinol Metab       Date:  2007-06-26       Impact factor: 5.958

10.  Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.

Authors:  Atul Sahai; Padmini Malladi; Hector Melin-Aldana; Richard M Green; Peter F Whitington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-03-25       Impact factor: 4.052

View more
  7 in total

1.  Sleeve Gastrectomy Reduces Body Weight and Improves Metabolic Profile also in Obesity-Prone Rats.

Authors:  Rafael Moncada; Sara Becerril; Amaia Rodríguez; Leire Méndez-Giménez; Beatriz Ramírez; Victoria Catalán; Javier Gómez-Ambrosi; M Jesús Gil; Secundino Fernández; Javier A Cienfuegos; Víctor Valentí; Gema Frühbeck
Journal:  Obes Surg       Date:  2016-07       Impact factor: 4.129

Review 2.  In Terms of Nutrition, the Most Suitable Method for Bariatric Surgery: Laparoscopic Sleeve Gastrectomy or Roux-en-Y Gastric Bypass? A Systematic Review and Meta-analysis.

Authors:  Lihu Gu; Rongrong Fu; Ping Chen; Nannan Du; Siqi Chen; Danyi Mao; Bangsheng Chen; Feiyan Mao; Parikshit Asutosh Khadaroo; Qiong Jin
Journal:  Obes Surg       Date:  2020-05       Impact factor: 4.129

Review 3.  A Systematic Review: Vitamin D Status and Sleeve Gastrectomy.

Authors:  Clare F Dix; Judith D Bauer; Olivia R L Wright
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

4.  Changes in Bone Metabolism After Sleeve Gastrectomy Versus Gastric Bypass: a Meta-Analysis.

Authors:  Zhao Tian; Xin-Tong Fan; Shi-Zhen Li; Ting Zhai; Jing Dong
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

5.  Changes in Nutritional Outcomes After Sleeve Gastrectomy: a Systematic Review and Meta-analysis.

Authors:  Yan Wang; Leizhen Duan; Xue Han; Jinjin Wang; Guoli Yan
Journal:  Obes Surg       Date:  2021-10-22       Impact factor: 4.129

Review 6.  Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy to Treat Morbid Obesity-Related Comorbidities: a Systematic Review and Meta-analysis.

Authors:  Jianfang Li; Dandan Lai; Dongping Wu
Journal:  Obes Surg       Date:  2016-02       Impact factor: 4.129

7.  Adherence to Nutritional Supplementation Determines Postoperative Vitamin D Status, but Not Levels of Bone Resorption Marker, in Sleeve-Gastrectomy Patients.

Authors:  Wen-Ling Liao; Wan-Ching Yang; Huey-Mei Shaw; Chi-Hsuan Lin; Chin-Ching Wu; Wan-Lin Hsu; Yao-Cheng Lu; Pei-Min Chao; Chih-Kun Huang
Journal:  Obes Surg       Date:  2021-05-25       Impact factor: 4.129

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.